| Gene symbol | KLRK1 | Synonyms | CD314, D12S2489E, KLR, NKG2-D, NKG2D | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p13.2 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | killer cell lectin like receptor K1 | ||||
| GTO ID | GTC1940 |
| Trial ID | NCT03612739 |
| Disease | Myelodysplastic Syndrome | Acute Myeloid Leukemia |
| Altered gene | NKG2D |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | NKR-2 |
| Co-treatment | 5-azacytidine |
| Generation | 1st |
| Phase | Phase1 |
| Recruitment status | Withdrawn |
| Title | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 |
| Year | 2018 |
| Country | Belgium |
| Company sponsor | Celyad Oncology SA |
| Other ID(s) | CYAD-N2T-006 |
| Cohort 1 | |||||||||
|
|||||||||